Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre

Overview of SARS-CoV-2 infection in adults living with HIV

(2021) Juan Ambrosioni et al.   Lancet HIV

Meta-Analysis of Efficacy and Safety of Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Among People Living with HIV

(2021) I-Wen Chen et al.   Infectious Diseases and Therapy

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose Two-Drug Regimen Versus Continuing a Tenofovir Alafenamide–Based Three- or Four-Drug Regimen for Maintenance of Virologic Suppression in Adults With HIV-1: Phase 3, Randomized, Non-inferiority TANGO Study

(2020) Jean van Wyk et al.   CLINICAL INFECTIOUS DISEASES

Antiretroviral resistance and management after pre-exposure prophylaxis

(2020) Victoria Tittle et al.   Lancet HIV

Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)

(2020) Rosa De Miguel et al.   EBioMedicine

Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV

(2020) Paul E Sax et al.   CLINICAL INFECTIOUS DISEASES

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-Existing NRTI Resistance

(2020) Rima K. Acosta et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0

(2020) L Ryom et al.   HIV MEDICINE

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

(2020) Michael S. Saag et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping

(2020) M Casadellà et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Analysis of inappropriate prescribing in elderly patients of the Swiss HIV Cohort Study reveals gender inequity

(2020) Françoise Livio et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Primary HIV-1 infection in users of pre-exposure prophylaxis

(2020) Juan Ambrosioni et al.   Lancet HIV

E157Q integrase strand-transfer inhibitor substitution in patients with acute/recent HIV infection

(2019) Juan Ambrosioni et al.   AIDS

Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I

(2019) Kristen Andreatta et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

(2018) Josep M Llibre et al.   LANCET

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

(2018) Jean-Michel Molina et al.   Lancet HIV

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial

(2018) Eric S Daar et al.   Lancet HIV

Epidemiological changes of acute/recent human immunodeficiency virus type 1 infection in Barcelona, Spain (1997–2015): a prospective cohort study

(2018) D. Nicolás et al.   CLINICAL MICROBIOLOGY AND INFECTION

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

(2018) Pedro Cahn et al.   LANCET

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

(2017) Paul E Sax et al.   LANCET

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

(2017) Joel Gallant et al.   LANCET

Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial

(2017) Paul E Sax et al.   Lancet HIV

Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute/recent HIV infection

(2016) J. Ambrosioni et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Trends in Transmission of Drug Resistance and Prevalence of Non-B Subtypes in Patients with Acute or Recent HIV-1 Infection in Barcelona in the Last 16 Years (1997-2012)

(2015) Juan Ambrosioni et al.   PLoS One

Update on antiretroviral treatment during primary HIV infection

(2014) Juan Ambrosioni et al.   Expert Review of Anti-Infective Therapy

Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement

(2012) Keith W Crawford et al.   LANCET INFECTIOUS DISEASES